Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo para explorar a eficácia de JNJ-89495120 no tratamento do transtorno depressivo maior (Moonlight-1)

24 de setembro de 2026 atualizado por: Janssen Research & Development, LLC

Um estudo randomizado, duplo-cego, multicêntrico, controlado por placebo e de prova de conceito para avaliar a eficácia, segurança e tolerabilidade de JNJ-89495120 como monoterapia em participantes adultos com transtorno depressivo maior (TDM)

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

Visão geral do estudo

Status

Concluído

Tipo de estudo

Intervencional

Inscrição (Real)

105

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alabama
      • Huntsville, Alabama, Estados Unidos, 35801
        • UAB Huntsville Regional Medical Campus
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Chandler Clinical Trials
      • Phoenix, Arizona, Estados Unidos, 85012
        • IMA Clinical Research PC Phoenix
      • Tucson, Arizona, Estados Unidos, 85724
        • University of Arizona
      • Tucson, Arizona, Estados Unidos, 85704
        • Noble Clinical Research
    • California
      • Bellflower, California, Estados Unidos, 90706
        • CI Trials
      • Encino, California, Estados Unidos, 91316
        • Wake Research PRI Encino
      • Garden Grove, California, Estados Unidos, 92844
        • National Institute Of Clinical Research
      • Newport Beach, California, Estados Unidos, 92660
        • WR-Newport Beach
      • Orange, California, Estados Unidos, 92866
        • ATP Clinical Research
      • Redlands, California, Estados Unidos, 92374
        • Anderson Clinical Research
      • San Diego, California, Estados Unidos, 92103
        • Artemis Institute for Clinical Research
      • San Jose, California, Estados Unidos, 95124
        • Lumos Clinical Research Center LLC
      • Santa Ana, California, Estados Unidos, 92705
        • Syrentis Clinical Research
      • Temecula, California, Estados Unidos, 92591
        • Inland Psychiatric Medical Group Inc
      • Walnut Creek, California, Estados Unidos, 94596
        • Sunwise Clinical Research
    • Colorado
      • Denver, Colorado, Estados Unidos, 80209
        • Mountain View Clinical Research
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33912
        • Gulfcoast Medical Research Center
      • Hollywood, Florida, Estados Unidos, 33021
        • The Medici Medical Research
      • Homestead, Florida, Estados Unidos, 33030
        • Advanced Research Institute of Miami
      • Maitland, Florida, Estados Unidos, 32751
        • K2 Medical Research
      • Miami, Florida, Estados Unidos, 33126
        • Pharmax Research Clinic Inc
      • Miami, Florida, Estados Unidos, 33135
        • Wellness Research Center
      • Pembroke Pines, Florida, Estados Unidos, 33024
        • Best Choice Medical and Research Service
      • Tampa, Florida, Estados Unidos, 33629
        • Interventional Psychiatry of Tampa Bay
      • West Palm Beach, Florida, Estados Unidos, 33407
        • Health Synergy Clinical Research
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Estados Unidos, 30030
        • iResearch Atlanta LLC
      • Snellville, Georgia, Estados Unidos, 30078
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Medical Center
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University IU Health
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70115
        • DelRicht Research
    • Maryland
      • Gaithersburg, Maryland, Estados Unidos, 20877
        • CBH Health
    • Massachusetts
      • Worcester, Massachusetts, Estados Unidos, 01655
        • University of Massachusetts Medical School
    • New York
      • Brooklyn, New York, Estados Unidos, 11229
        • Integrative Clinical Trials LLC
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • University of Cincinnati
      • Cincinnati, Ohio, Estados Unidos, 45215
        • Patient Priority Clinical Sites LLC
      • Columbus, Ohio, Estados Unidos, 43210
        • OSU Department of Psychiatry and Behavioral Health
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73116
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania
    • South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29405
        • Coastal Carolina Research Center
    • Texas
      • McKinney, Texas, Estados Unidos, 75071
        • Revival Research Institute LLC
    • Utah
      • Clinton, Utah, Estados Unidos, 84015
        • Alpine Research Organization
    • Washington
      • Everett, Washington, Estados Unidos, 98201
        • Core Clinical Research

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 64 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm 1: JNJ-89495120 Dose A

Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

JNJ-89495120 will be administered.

Experimental: Arm 2: JNJ-89495120 Dose A and Dose B

Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

JNJ-89495120 will be administered.

Comparador de Placebo: Arm 3: Placebo Group

Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

Placebo will be administered.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Prazo: Baseline up to Day 5

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 5

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in MADRS Total Score to Day 2
Prazo: Baseline up to Day 2

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 2
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Prazo: Baseline up to Day 2 and Day 5

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

Baseline up to Day 2 and Day 5
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Prazo: Baseline up to Day 5

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

Baseline up to Day 5
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Prazo: Baseline up to Day 5

The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

Baseline up to Day 5
Number of Participants with Adverse Events (AEs)
Prazo: Up to approximately 18 weeks

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to approximately 18 weeks
Number of Participants with Abnormalities in Vital Signs Parameters
Prazo: Up to approximately 18 weeks

Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

Up to approximately 18 weeks
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Prazo: Up to approximately 18 weeks

Participants with 12-lead ECG abnormalities will be reported.

Up to approximately 18 weeks
Number of Participants With Abnormalities in Laboratory Parameters
Prazo: Up to approximately 18 weeks

Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

Up to approximately 18 weeks
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Prazo: Up to approximately 18 weeks

Participants with changes in weight/BMI will be reported.

Up to approximately 18 weeks
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Prazo: Up to approximately 18 weeks

The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

Up to approximately 18 weeks
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Prazo: From Baseline up to 4 weeks

The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

From Baseline up to 4 weeks
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Prazo: From Baseline up to 4 weeks

The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

From Baseline up to 4 weeks
Plasma Concentrations of JNJ-89495120
Prazo: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Plasma concentrations of JNJ-89495120 will be reported.

Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

26 de dezembro de 2024

Conclusão Primária (Real)

25 de junho de 2026

Conclusão do estudo (Real)

10 de agosto de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

15 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de janeiro de 2025

Primeira postagem (Real)

20 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 89495120MDD2001
  • 89495120MDD2001 (Outro identificador: Janssen Research & Development, LLC)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever